Uniquity Bio, a clinical-stage biotechnology company focused on immunology and inflammation, has announced positive topline results from its Phase II ALAMERE trial evaluating solrikitug in adults with eosinophilic esophagitis (EoE).
The investigational monoclonal antibody, which targets thymic stromal lymphopoietin (TSLP), demonstrated statistically significant and clinically meaningful improvements across both co-primary endpoints and key secondary endpoints at Week 24. Results were observed across all three doses tested: 125 mg, 250 mg and 500 mg.
Solrikitug was generally well tolerated and showed a favourable safety profile. Based on the findings, Uniquity Bio plans to initiate a pivotal Phase III trial in the first quarter of 2027.
Key Highlights
-
Positive topline results from the Phase II ALAMERE trial in adults with EoE.
-
Solrikitug met both co-primary endpoints across all three doses tested.
-
Placebo-corrected histologic remission rates ranged from 69% to 76% at Week 24.
-
Dysphagia symptoms improved by 8.8–12.6 points compared with placebo.
-
Improvements were also observed in endoscopic and histologic disease measures.
-
Solrikitug was well tolerated, with a favourable safety profile.
-
Uniquity Bio plans to begin a pivotal Phase III trial in Q1 2027.
Phase II ALAMERE Trial Results
The ALAMERE study was a randomised, double-blind, placebo-controlled Phase II trial designed to evaluate the efficacy and safety of solrikitug at three dose levels in adults with eosinophilic esophagitis.
Solrikitug was administered subcutaneously every four weeks. The study evaluated three doses: 125 mg, 250 mg and 500 mg.
The trial achieved both co-primary endpoints at Week 24:
1. Histologic remission
Histologic remission was assessed through eosinophil counts in oesophageal tissue. Solrikitug achieved placebo-corrected histologic remission rates of 69%–76% across all three doses, with statistically significant results (p<0.001).
2. Improvement in dysphagia symptoms
Dysphagia symptoms, including difficulty or discomfort while swallowing, were measured using the Dysphagia Symptom Questionnaire (DSQ).
Solrikitug reduced the frequency and severity of dysphagia symptoms by 8.8–12.6 points compared with placebo across the three doses tested. The improvements were statistically significant, with p-values below 0.05, 0.01 and 0.001, respectively.
Improvements in Secondary Endpoints
The study also demonstrated meaningful improvements in key secondary endpoints, including:
-
EoE Endoscopic Reference Score (EREFS).
-
Histologic disease activity measured using the EoE Histology Scoring System (EoE-HSS).
-
Dysphagia-free days.
-
Safety and tolerability.
Uniquity Bio is continuing to monitor participants through Week 52 to assess the durability of treatment response and longer-term clinical safety. Full study results are expected to be presented at a future medical congress.
How Solrikitug Works
Solrikitug is an investigational, highly potent monoclonal antibody designed to target thymic stromal lymphopoietin (TSLP), an epithelial-cell-derived cytokine involved in inflammatory and allergic immune responses.
By inhibiting TSLP, solrikitug aims to interfere with inflammatory pathways associated with eosinophilic esophagitis.
The Phase II findings support further investigation of this mechanism in EoE and suggest the potential for an extended dosing interval beyond four weeks. However, the optimal dosing schedule and longer-term benefits will require confirmation in further clinical studies.
Understanding Eosinophilic Esophagitis
Eosinophilic esophagitis is a chronic inflammatory condition of the oesophagus, commonly triggered by an allergic immune response. It involves the accumulation of eosinophils, a type of white blood cell, in the oesophageal tissue.
Common symptoms include:
-
Difficulty swallowing.
-
Food getting stuck in the oesophagus.
-
Chest pain.
-
Vomiting.
-
Abdominal pain.
EoE is estimated to affect approximately 470,000 people in the United States. Its prevalence has increased around five-fold since 2009, according to the company.
If left inadequately controlled, chronic inflammation may lead to oesophageal fibrosis and strictures, potentially causing persistent swallowing difficulties. Despite available treatment approaches, significant unmet medical needs remain for patients who do not achieve adequate symptom and disease control.
Uniquity Bio Plans Phase III Development in 2027
Following the positive ALAMERE results, Uniquity Bio is preparing to initiate a pivotal Phase III trial in the first quarter of 2027.
The company reported positive discussions with the US Food and Drug Administration (FDA) following completion of Phase II. According to Uniquity Bio, a single pivotal Phase III study, together with ALAMERE as confirmatory evidence, could provide the clinical evidence needed to support a planned Biologics License Application (BLA).
The company is also advancing Phase II programmes in asthma and chronic obstructive pulmonary disease (COPD). In parallel, it is evaluating potential bispecific and combination product candidates that could target additional inflammatory pathways.
Solrikitug was in-licensed from Merck & Co., Inc., known as MSD outside the United States and Canada.
What This Means for EoE Treatment
The ALAMERE results represent an important clinical development milestone for solrikitug and provide further evidence supporting TSLP inhibition as a potential therapeutic approach in eosinophilic esophagitis.
The improvements across histologic remission, swallowing symptoms and other disease measures suggest that solrikitug could become a potential treatment option if its benefits are confirmed in pivotal trials.
With Phase III development planned for 2027, the next stage will be important in establishing its efficacy, safety and potential role in the treatment of EoE.
Solrikitug remains investigational and is not yet approved for the treatment of eosinophilic esophagitis.